Coxibs and serious adverse cardiovascular events: a class-effect?

Arthritis medicines and cardiovascular events--"house of coxibs".

PHYSICIANS, PATIENTS, AND THE GENERAL PUBLIC ARE confronted with an acute confusional state regarding the cardiovascular safety of medicines for arthritis. Since September 30, 2004, the day that rofecoxib was precipitously withdrawn, there has hardly been a day without significant news on the general topic of cyclooxygenase 2 (COX-2) inhibitors. On December 9, 2004, the US Food and Drug Adminis...

Coxibs and cardiovascular disease.

Coxibs and cardiovascular risk.

J Cotter and Eric Wooltorton highlight the importance of differences in cyclooxygenase 2 (COX-2) selectivity as a potential explanation for the prothrombotic effects of coxibs. However, they neglect important evidence that celecoxib might not share the same cardiovascular (CV) risk as rofecoxib. An increased thrombotic risk with celecoxib has been demonstrated only in the APC (Adenoma Preventio...

Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

BACKGROUND There have been postmarketing reports of adverse cardiovascular events associated with the use of varenicline, a widely used smoking cessation drug. We conducted a systematic review and meta-analysis of randomized controlled trials to ascertain the serious adverse cardiovascular effects of varenicline compared with placebo among tobacco users. METHODS We searched MEDLINE, EMBASE, t...

[Cardiovascular events: a class effect by COX-2 inhibitors].

Non-steroidal anti-inflamatories (NSAIDs) are widely used in the treatment of post-surgery pain1, osteoarthritis2, rheumatoid arthritis3 and muscle-skeletal pain4,5, in different conditions. Major effects are: anti-inflammatory, analgesic, and antipyretic6. Generally speaking, such effects are associated to the inhibition of the enzyme cyclooxygenase (COX). COX catalyzes the transformation of a...